X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
According to the agreement, Alvotech will be responsible for development and manufacture, while Polifarma will handle market registration and commercialization of AVT06, a recombinant fusion protein and a biosimilar candidate to Eylea® (aflibercept).
Lead Product(s): Aflibercept
Therapeutic Area: Ophthalmology Product Name: AVT06
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Alvotech
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 10, 2023
Details:
According to the agreement, Dong-A ST will license out the exclusive rights for the development and commercialization of DA-3880 (darbepoetin alfa). DA-3880 is an ARANESP/NESP biosimilar for the treatment of anemic patients with chronic renal failure.
Lead Product(s): Darbepoetin alfa
Therapeutic Area: Hematology Product Name: DA-3880
Highest Development Status: ApprovedProduct Type: Large molecule
Recipient: Dong-A ST Co., Ltd.
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 09, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
